Perspective Therapeutics’ (CATX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Perspective Therapeutics (NYSE:CATX) in a report issued on Wednesday,Benzinga reports. HC Wainwright currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Perspective Therapeutics’ FY2025 earnings at ($1.20) EPS.

CATX has been the topic of a number of other research reports. Brookline Capital Management upgraded Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. Scotiabank initiated coverage on shares of Perspective Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a report on Monday, March 17th. Lifesci Capital upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Finally, Oppenheimer cut their price objective on shares of Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating for the company in a research report on Friday, November 22nd. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $14.56.

Perspective Therapeutics Stock Performance

NYSE:CATX opened at $2.52 on Wednesday. Perspective Therapeutics has a 12-month low of $2.32 and a 12-month high of $19.05. The stock’s 50 day moving average price is $3.03 and its two-hundred day moving average price is $6.86.

Institutional Investors Weigh In On Perspective Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. FMR LLC grew its position in Perspective Therapeutics by 3,994.9% during the third quarter. FMR LLC now owns 5,504,822 shares of the company’s stock worth $73,489,000 after buying an additional 5,370,392 shares in the last quarter. Millennium Management LLC bought a new stake in shares of Perspective Therapeutics during the 4th quarter valued at $4,132,000. State Street Corp grew its holdings in shares of Perspective Therapeutics by 119.6% during the 3rd quarter. State Street Corp now owns 2,190,239 shares of the company’s stock worth $29,240,000 after purchasing an additional 1,192,812 shares in the last quarter. Octagon Capital Advisors LP increased its position in shares of Perspective Therapeutics by 62.1% in the fourth quarter. Octagon Capital Advisors LP now owns 2,304,752 shares of the company’s stock worth $7,352,000 after purchasing an additional 882,528 shares during the period. Finally, Affinity Asset Advisors LLC raised its stake in Perspective Therapeutics by 160.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after purchasing an additional 800,000 shares in the last quarter. 54.66% of the stock is currently owned by institutional investors and hedge funds.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.